Posters and Oral presentations
ESMO Immuno-Oncology Congress 2019, December 2019 - POSTER
Multiple KRAS and changing mutations detected by cancer related KRAS DNA in patients with resected pancreas ductal adenocarcinoma during treatment with TG01/GM-CSF and gemcitabine (CT TG01-01)
ASCO Annual Conference 2018 - POSTER
A Phase I/II trial of TG01/GM-CSF and Adjuvant Gemcitabine in Patients With Resected RAS-mutant Adenocarcinoma of the Pancreas
ESMO 2017 Congress, September 2017 – POSTER
TG01/GM-CSF and Adjuvant Gemcitabine in Patients With Resected RAS-mutant Adenocarcinoma of the Pancreas
ESMO 2017 Congress, September 2017 – POSTER
An Observational Clinical Study With RAS Peptide Vaccine Tg01 Evaluating Immune Response, Safety and Overall Survival in Patients With Non-resectable Pancreatic Cancer
ASCO Annual Meeting, June 2017 – POSTER
A Phase I/II Trial of TG01/GM-CSF and Gemcitabine as adjuvant therapy for treating patients with resected RAS-mutant adenocarcinoma of the pancreas
ASCO Annual Meeting, May 2015 - POSTER
A prospective, single-arm, phase I/II trial of RAS peptide vaccine TG01/GM-CSF and gemcitabine as adjuvant therapy for patients with resected pancreatic adenocarcinoma.
CIMT Annual Meeting, May 2014 – POSTER & ORAL PRESENTATION
A Phase I/II Trial of TG01 and Gemcitabine in patients with resected pancreatic cancer; Phase I results